INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
| Autor: | Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M Tho, Xiuning Le, Julien Mazieres, How S Hin, Masahire Morise, Viola W Zhu, Daniel Tan, Kristina H Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M Schumacher, Niki Karachaliou, Yi-Long Wu |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
OUTCOMES
Cancer Research Science & Technology CELL LUNG-CANCER IN-SITU MULTICENTER AMPLIFICATION EGFR TKI General Medicine MECHANISMS non-small-cell lung cancer FISH Oncology osimertinib CRITERIA EGFR tyrosine kinase inhibitors INHIBITOR TEPOTINIB Life Sciences & Biomedicine tepotinib MET amplification |
| Zdroj: | Future Oncology. 18:1039-1054 |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | MET amplification (METamp), a mechanism of acquired resistance to EGFR tyrosine kinase inhibitors, occurs in up to 30% of patients with non-small-cell lung cancer (NSCLC) progressing on first-line osimertinib. Combining osimertinib with a MET inhibitor, such as tepotinib, an oral, highly selective, potent MET tyrosine kinase inhibitor, may overcome METamp-driven resistance. INSIGHT 2 (NCT03940703), an international, open-label, multicenter phase II trial, assesses tepotinib plus osimertinib in patients with advanced/metastatic EGFR-mutant NSCLC and acquired resistance to first-line osimertinib and METamp, determined centrally by fluorescence in situ hybridization (gene copy number ≥5 and/or MET/CEP7 ≥2) at time of progression. Patients will receive tepotinib 500 mg (450 mg active moiety) plus osimertinib 80 mg once-a-day. The primary end point is objective response, and secondary end points include duration of response, progression-free survival, overall survival and safety. Trial registration number: NCT03940703 (clinicaltrials.gov). ispartof: FUTURE ONCOLOGY vol:18 issue:9 pages:1039-1054 ispartof: location:England status: published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|